Listen ad-free

Election Watch: The New Statesman podcast | daily throughout the UK general election

The New Statesman

The New Statesman podcast is now daily.

As the UK prepares to vote in a new government on July 4, join host Hannah Barnes is joined by NS journalists including veteran broadcaster Andrew Marr for daily discussion of the latest election developments including reaction from around the UK, polling analysis with expert Ben Walker, and a regular listener questions episode every Friday.

New episodes publish at 5pm Monday-Friday.


Send us a question:

Become a New Statesman subscriber:

Hosted on Acast. See for more information.

read less


The race to cervical cancer elimination | Sponsored
The race to cervical cancer elimination | Sponsored
Cervical cancer is the fourth most common cancer in women globally. It causes more than 800 deaths in the UK each year. Yet 99.8% of cervical cancer cases are entirely preventable. Regular screening and the introduction of the Human Papillomavirus (HPV) vaccination are helping to reduce the number of deaths. With smart policy and public health interventions NHS England have set 2040 as the target date for total elimination of cervical cancer. If that goal is to be met the issue of health inequality needs to be addressed; currently screening and vaccination rates vary between different regions, communities and socio-economic groups. So what needs to be done to share best practice and narrow these inequalities? In this episode of Spotlight on Policy, host Zoe Grunwald is joined by Emma Cerrone, Business Unit Director for Public Health & Vaccines at MSD; Dr Adeola Olaitan, Honorary Associate Professor at University College London and Honorary Consultant Gynaecological Oncologist at UCLH; and Gayathri Kumar, Senior Economist at OHE, the Office for Health Economics. This episode has been fully funded by MSD who, as sponsors, have reviewed and inputted to the final content. The report referenced by Office for Health Economics throughout this episode was fully funded by MSD. Ultimate editorial control for this episode and the OHE report rests solely with the New Statesman and the Office for Health Economics, respectively. MSD is one of the world’s leading pharmaceutical companies active in several key areas of global health, including immunisation and oncology. Hosted on Acast. See for more information.